Literature DB >> 29619607

Pharmacokinetic/Pharmacodynamic Considerations of Beta-Lactam Antibiotics in Adult Critically Ill Patients.

Anne M Masich1, Mojdeh S Heavner1, Jeffrey P Gonzales1, Kimberly C Claeys2.   

Abstract

PURPOSE OF REVIEW: Beta-lactam antibiotics are commonly prescribed in critically ill patients for a variety of infectious conditions. Our understanding of how critical illness alters beta-lactam pharmacokinetics/pharmacodynamics (PK/PD) is rapidly evolving. RECENT
FINDINGS: There is a growing body of literature in adult patients demonstrating that physiological alterations occurring in critically ill patients may limit our ability to optimally dose beta-lactam antibiotics to reach these PK/PD targets. These alterations include changes in volume of distribution and renal clearance with multiple, often overlapping causative pathways, including hypoalbuminemia, renal replacement therapy, and extracorporeal membrane oxygenation. Strategies to overcome these PK alterations include extended infusions and therapeutic drug monitoring. Combined data has demonstrated a possible survival benefit associated with extending beta-lactam infusions in critically ill adult patients. This review highlights research on physiological derangements affecting beta-lactam concentrations and strategies to optimize beta-lactam PK/PD in critically ill adults.

Entities:  

Keywords:  Beta-lactams; Critically ill; Extracorporeal membrane oxygenation; Pharmacodynamics; Pharmacokinetics; Renal replacement therapy

Year:  2018        PMID: 29619607     DOI: 10.1007/s11908-018-0613-1

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  63 in total

1.  TDM-guided therapy with daptomycin and meropenem in a morbidly obese, critically ill patient.

Authors:  Federico Pea; Piergiorgio Cojutti; Rodolfo Sbrojavacca; Barbara Cadeo; Francesco Cristini; Alessandro Bulfoni; Mario Furlanut
Journal:  Ann Pharmacother       Date:  2011-07-12       Impact factor: 3.154

2.  Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort.

Authors:  Mohd H Abdul-Aziz; Jeffrey Lipman; Murat Akova; Matteo Bassetti; Jan J De Waele; George Dimopoulos; Joel Dulhunty; Kirsi-Maija Kaukonen; Despoina Koulenti; Claude Martin; Philippe Montravers; Jordi Rello; Andrew Rhodes; Therese Starr; Steven C Wallis; Jason A Roberts
Journal:  J Antimicrob Chemother       Date:  2015-10-03       Impact factor: 5.790

3.  Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis.

Authors:  Eduardo Asín-Prieto; Alicia Rodríguez-Gascón; Iñaki F Trocóniz; Amaia Soraluce; Javier Maynar; José Ángel Sánchez-Izquierdo; Arantxazu Isla
Journal:  J Antimicrob Chemother       Date:  2013-08-01       Impact factor: 5.790

4.  Acute renal failure in patients with sepsis in a surgical ICU: predictive factors, incidence, comorbidity, and outcome.

Authors:  Eric A J Hoste; Norbert H Lameire; Raymond C Vanholder; Dominique D Benoit; Johan M A Decruyenaere; Francis A Colardyn
Journal:  J Am Soc Nephrol       Date:  2003-04       Impact factor: 10.121

5.  A Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis.

Authors:  Joel M Dulhunty; Jason A Roberts; Joshua S Davis; Steven A R Webb; Rinaldo Bellomo; Charles Gomersall; Charudatt Shirwadkar; Glenn M Eastwood; John Myburgh; David L Paterson; Therese Starr; Sanjoy K Paul; Jeffrey Lipman
Journal:  Am J Respir Crit Care Med       Date:  2015-12-01       Impact factor: 21.405

Review 6.  Pharmacokinetic/pharmacodynamic considerations for the optimization of antimicrobial delivery in the critically ill.

Authors:  Danny Tsai; Jeffrey Lipman; Jason A Roberts
Journal:  Curr Opin Crit Care       Date:  2015-10       Impact factor: 3.687

7.  The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: a matched cohort study.

Authors:  Kiran Shekar; John F Fraser; Fabio Silvio Taccone; Susan Welch; Steven C Wallis; Daniel V Mullany; Jeffrey Lipman; Jason A Roberts
Journal:  Crit Care       Date:  2014-12-12       Impact factor: 9.097

Review 8.  Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock--does the dose matter?

Authors:  Federico Pea; Pierluigi Viale
Journal:  Crit Care       Date:  2009-06-10       Impact factor: 9.097

9.  DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients?

Authors:  Jason A Roberts; Sanjoy K Paul; Murat Akova; Matteo Bassetti; Jan J De Waele; George Dimopoulos; Kirsi-Maija Kaukonen; Despoina Koulenti; Claude Martin; Philippe Montravers; Jordi Rello; Andrew Rhodes; Therese Starr; Steven C Wallis; Jeffrey Lipman
Journal:  Clin Infect Dis       Date:  2014-01-14       Impact factor: 9.079

10.  Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenation.

Authors:  Kiran Shekar; Jason A Roberts; Charles I Mcdonald; Stephanie Fisquet; Adrian G Barnett; Daniel V Mullany; Sussan Ghassabian; Steven C Wallis; Yoke L Fung; Maree T Smith; John F Fraser
Journal:  Crit Care       Date:  2012-10-15       Impact factor: 9.097

View more
  7 in total

Review 1.  Carbapenem-Resistant Enterobacteriaceae in Solid Organ Transplantation: Management Principles.

Authors:  Olivia Smibert; Michael J Satlin; Anoma Nellore; Anton Y Peleg
Journal:  Curr Infect Dis Rep       Date:  2019-06-10       Impact factor: 3.725

2.  A Review of Extended and Continuous Infusion Beta-Lactams in Pediatric Patients.

Authors:  Taylor A Imburgia; Michelle L Kussin
Journal:  J Pediatr Pharmacol Ther       Date:  2022-03-21

3.  Challenging T > MIC Using Meropenem vs. Escherichia coli and Pseudomonas aeruginosa.

Authors:  A Nussbaumer-Pröll; S Eberl; E Kurdina; L Schmidt; M Zeitlinger
Journal:  Front Pharmacol       Date:  2022-04-01       Impact factor: 5.810

4.  Clinical outcomes of empirical high-dose meropenem in critically ill patients with sepsis and septic shock: a randomized controlled trial.

Authors:  Tospon Lertwattanachai; Preecha Montakantikul; Viratch Tangsujaritvijit; Pitsucha Sanguanwit; Jetjamnong Sueajai; Saranya Auparakkitanon; Pitchaya Dilokpattanamongkol
Journal:  J Intensive Care       Date:  2020-04-15

Review 5.  The Minimum Inhibitory Concentration of Antibiotics: Methods, Interpretation, Clinical Relevance.

Authors:  Beata Kowalska-Krochmal; Ruth Dudek-Wicher
Journal:  Pathogens       Date:  2021-02-04

6.  Dose optimization of β-lactams antibiotics in pediatrics and adults: A systematic review.

Authors:  Abdul Haseeb; Hani Saleh Faidah; Saleh Alghamdi; Amal F Alotaibi; Mahmoud Essam Elrggal; Ahmad J Mahrous; Safa S Almarzoky Abuhussain; Najla A Obaid; Manal Algethamy; Abdullmoin AlQarni; Asim A Khogeer; Zikria Saleem; Muhammad Shahid Iqbal; Sami S Ashgar; Rozan Mohammad Radwan; Alaa Mutlaq; Nayyra Fatani; Aziz Sheikh
Journal:  Front Pharmacol       Date:  2022-09-21       Impact factor: 5.988

7.  A Translational Pharmacokinetic Rat Model of Cerebral Spinal Fluid and Plasma Concentrations of Cefepime.

Authors:  Sean N Avedissian; Gwendolyn Pais; Medha D Joshi; Nathaniel J Rhodes; Marc H Scheetz
Journal:  mSphere       Date:  2019-01-30       Impact factor: 4.389

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.